Early Experience With Eravacycline for Complicated Infections-Reference-Cited by-同舟云学术

Early Experience With Eravacycline for Complicated Infections

Published:2020-03-02 Issue:5 Volume:7 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Alosaimy Sara¹,Molina Kyle C²,Claeys Kimberly C³,Andrade Justin⁴,Truong James⁴,King Madeline A⁵⁶,Pullinger Benjamin M⁵⁶,Huang Glen⁷,Morrisette Taylor¹,Lagnf Abdalhamid M¹,Davis Susan L¹⁸,Rybak Michael J¹⁹¹⁰

Affiliation:

1. Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit ,Michigan, USA

2. University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA

3. Univeristy of Maryland School of Pharmacy, Baltimore, Maryland, USA

4. The Brooklyn Hospital Center, Brooklyn, New York, USA

5. Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, Pennsylvania, USA

6. Cooper University Hospital, Camden, New Jersey, USA

7. Univeristy of California Los Angeles, California, USA

8. Department of Pharmacy, Henry Ford Hospital, Detroit, Michigan, USA

9. Department of Pharmacy, Detroit Medical Center, Detroit, Michigan, USA

10. Department of Medicine, Division of Infectious Diseases, School of Medicine, Wayne State University, Detroit, Michigan, USA

Abstract

Abstract Eravacycline (ERV) was used in 35 patients for various infections. The most common pathogen was Klebsiella pneumoniae, and 30-day survival was 74%. Absence of 30-day recurrence and resolution of signs and symptoms of infection were 91% and 57%, respectively. ERV was well-tolerated, with adverse events leading to drug discontinuation in one patient.

Funder

Tetraphase

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofaa071/32740178/ofaa071.pdf

Reference12 articles.

1. Antibiotic resistance threats in the United States, 2019

2. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) trial: a randomized clinical trial;Solomkin;JAMA Surg,2017

3. IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs. meropenem in the treatment of complicated intra-abdominal infections;Solomkin;Clin Infect Dis,2019